Month: April 2021

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021. Dr. Tucker’s presentation titled, “Vaxart oral COVID-19 vaccine; hold the ice and the needles,” will provide insight into the Company’s response and approach to addressing the COVID-19 pandemic with a room temperature oral tablet vaccine that is potentially protective against new and emerging COVID-19 strains. Presentation details are as follows:Title: Vaxart oral COVID-19 vaccine; hold the ice and the needlesTrack:...

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its novel implantable subcutaneous product and its use in the prevention of psychedelic drug diversion. LSD and psilocybin microdosing are currently in multiple ongoing clinical trials.  One major overlooked issue is the possibility of the patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose or resale of the drugs to someone other than the patient.  BetterLife’s invention has solved this problem by use of an implant administered...

INDIANAPOLIS, April 29, 2021 (GLOBE NEWSWIRE) — Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today that it will release fiscal first quarter 2021 financial results on Thursday, May 13, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5247226; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Apria Apria is a leading...

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 10, 2021, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2021. To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13719428. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be...

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that it will report first quarter 2021 financial results on Thursday, May 6, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay of the webcast will be available on the Company’s website until May 13, 2021. Audio...

TORONTO, April 29, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTC: WKSP) (or the “Company”) is excited to update its investors, shareholders, and supporters that it is in the final stages of negotiations for the leasing of their brand-new manufacturing facility. This major strategic manufacturing investment will provide the necessary infrastructure to support the Company’s growth while mass-producing its TerraVis™ tonneau cover systems & TerraVis COR™ battery systems, the former to be fully assembled in Canada. Once finalized, this move will facilitate unique, valuable opportunities that will afford Worksport’s business to grow into the space. One of the most important operational facets of the Company has always been to ensure scalability in Worksport’s manufacturing processes. This factory will not only support Worksport’s forthcoming...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Merit Cudkowicz, M.D., to its board of directors. “We are thrilled to add Dr. Cudkowicz to the Praxis board of directors. As a world-renowned leader in neurology with a background in innovative, patient-guided clinical research, Dr. Cudkowicz will help drive us toward our goal of providing therapies to patients in need,” said Marcio Souza, president and chief executive officer of Praxis. Dr. Cudkowicz is the chief of neurology at Mass General Hospital, director of the Sean M. Healey & AMG Center for ALS, and...

ILUS 04-29ILUS – Autonomous Firefighting VehicleNEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — ILUS International Inc is a Mergers and Acquisitions company focused on acquiring and developing technology-based companies globally. In addition to the 3 successful acquisitions already completed in 2021, Ilus has also entered into several Technology Partnerships, Joint Ventures and Memorandums of Understanding with companies whose innovative technology is disrupting their respective industries and which complements the Ilus strategy and vision. In line with this, one of Ilus’ acquisitions, FireBug, entered into a Memorandum of Understanding with Milanion Group in February 2021, for the purpose of developing an Autonomous Firefighting Vehicle based on the existing Milanion Agema Unmanned Ground...

VAN NUYS, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Eco Innovation Group, Inc. (OTC:ECOX) (“ECOX” or the “Company”), an innovative company aggregating investments in new technologies that promote environmental and social well-being and the advancement of green energy solutions, is pleased to announce the release of a new video developed by the Company to help current and prospective investors better understand the mission and market positioning of Eco Innovation Group. View the new video Here. The video may also be found on the Company’s website at www.ecoig.com. Julia Otey-Raudes, President and CEO of Eco Innovation Group, commented, “This video is a very straightforward account of why this Company exists: we believe – not just in creating a more sustainable future for the planet and everyone and everything...

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will host a conference call and live audio webcast on Wednesday, May 5, 2021 at 5:00 p.m. ET to report its first quarter 2021 financial results and provide a corporate update. In order to participate in the conference call, please dial 800-708-4539 (toll free) or 847-619-6396 (toll) and refer to confirmation number 50156207. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website...